RWE: Italy
Efficacy
PFS
OS
| Safety |
|---|
| Safety data was not reported by product |
“The PFS and OS is similar across histotypes and between products”
- Reference: 1. Chiappella A et al. American Society of Hematology Annual Meeting, 11–14 December 2021, Atlanta, GA. Abstract 3867.
Data collection
Mar 2019–Jun 2021
Società Italiana di Ematologia (SIE)
Median follow-up
months
No. of patients infused with tisa-cel
| Median age (range) years | 53 (19–70) |
| Gender (male) | NR |
| ECOG ≥2 | NR |
| IPI | NR |
| HG lymphoma (double or triple hit) | 12% |
| DLBCL | 70% |
| Transformed lymphoma | NR |
| Comorbidities | NR |
| LDH elevated | NR |
| Prior therapies, median (IQR)≥3 lines | 3 (2–12)NR |
| Primary refractoryRefractory to last lineRelapsed | 69%NRNR |
| Prior SCTAutoAllo | 30%NR |
| Bridging therapy | 93% |
Limitations: RWE source with youngest population and no patients >70 years, but with limitation that baseline characteristics are grouped for both products
- Reference: 1. Chiappella A et al. American Society of Hematology Annual Meeting, 11–14 December 2021, Atlanta, GA. Abstract 3867.
Patient
summary
Your patient summary will be shown here as you save you patient selections
This is where your patient summary will be shown. If you would like more tailored data, create a patient profile
Start a patient profile3L+ DLBCL PATIENT
Patient profile
- Incomplete
Treatment history
- Incomplete
Treatment choice
- Incomplete